Despite significant progress in clinical management, drug resistance remains a major
obstacle. Recent research based on protein degradation to restrain drug resistance has …

The field of targeted protein degradation (TPD) is a rapidly developing therapeutic modality
with the promise to tame disease-relevant proteins in ways that are difficult or impossible to …

Highlights•Drug resistance towards chemotherapy and molecularly targeted therapies
remains a great challenge in cancer treatments.•Deubiquitinating enzymes (DUBs) regulate …

Drug resistance is a well-known phenomenon leading to a reduction in the effectiveness of
pharmaceutical treatments. Resistance to chemotherapeutic agents can involve various …

Proteasome inhibitors have shown relevant clinical activity in several hematological
malignancies, namely in multiple myeloma and mantle cell lymphoma, improving patient …

Targeting of the protein degradation pathway, in particular, the ubiquitin-proteasome system,
has emerged as an attractive novel cancer chemotherapeutic modality. Although …

Targeting pathogenic proteins with small-molecule inhibitors (SMIs) has become a widely
used strategy for treating malignant tumors. However, most intracellular proteins have been …

In a time of unprecedented challenges in developing potent, selective and well-tolerated
protein inhibitors as therapeutics, drug hunters are increasingly seeking alternative …

The human proteome contains approximately 20,000 proteins, and it is estimated that more
than 600 of them are functionally important for various types of cancers, including nearly 400 …

With the approval by the US Food and Drug Administration of bortezomib for the treatment of
multiple myeloma and mantle cell lymphoma, the proteasome was clinically validated as a …